 A large number of molecular alterations are under study for their prognostic impact in AML . However , only FLT3 @-@ ITD , NPM1 , CEBPA and c @-@ KIT are currently included in validated international risk stratification schema . These are expected to increase rapidly in the near future . FLT3 internal tandem duplications ( ITDs ) have been shown to confer a poorer prognosis in AML with normal cytogenetics . Several FLT3 inhibitors have undergone clinical trials , with mixed results . Two other mutations - NPM1 and biallelic CEBPA are associated with improved outcomes , especially in people with normal cytogenetics and are used in current risk stratification algorithms . 
 A large number of molecular alterations are under study for their prognostic impact in AML . However , only FLT3 @-@ ITD , NPM1 , CEBPA and c @-@ KIT are currently included in validated international risk stratification schema . These are expected to increase rapidly in the near future . FLT3 internal tandem duplications ( ITDs ) <a href='been_done' title='1'><mark>have</mark></a> been shown to confer a poorer prognosis in AML with normal cytogenetics . Several FLT3 inhibitors <a href='been_done' title='2'><mark>have</mark></a> undergone clinical trials , with mixed results . Two other mutations - NPM1 and biallelic CEBPA are associated with improved outcomes , especially in people with normal cytogenetics and are used in current risk stratification algorithms . 
A bigass number of molecular alterations are under study for their prognostic impact in AML . However , only FLT3 @-@ ITD , NPM1 , CEBPA and c @-@ KIT r currently included in validated international risk stratification schema . dese arrxpected to increase rapidly in the near future . FLT3 internal tandem duplications ( ITDs ) done been shown to confer a poorer prognosis in AML with normal cytogenetics . Several FLT3 inhibitors done undergone clinical trials , with mixed results . 2 other mutations - NPM1 and biallelic CEBPA are rociated wit improved outcomes , especially in ppl wwnormal cytogenetics and are used in current risk stratification algorithms .